Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizia Borsotti

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Connective Tissue Research|May 7, 2015
Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenograftsDenise Pinessi, Paola Ostano, Patrizia Borsotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulatorGurmeet Kaur, Dorina Belotti, Angelika M Burger, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2013
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinibMassimo Zucchetti, Katiuscia Bonezzi, Roberta Frapolli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivativeGiulia Taraboletti, Gianluca Micheletti, Monica Rieppi, et al.
Pharmacological Research|April 29, 2026
HIJACKING CLIENT INSTABILITY TO SELECTIVELY DISRUPT HSP90-DRIVEN GLUCOCORTICOID RECEPTOR ACTIVATIONElisa Longhi, Andrea Magni, Luca Torielli, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|October 15, 2021
Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activityDenise Pinessi, Andrea Resovi, Fabio Sangalli, et al.
Angiogenesis|September 1, 2018
The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2)Marco Rusnati, Patrizia Borsotti, Elisabetta Moroni, et al.
International Journal of Cancer|June 12, 2014
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1Romina Dossi, Roberta Frapolli, Silvana Di Giandomenico, et al.
Pigment Cell & Melanoma Research|September 27, 2014
Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2Patrizia Borsotti, Carmen Ghilardi, Paola Ostano, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 9, 2023
Fibronectin fragments generated by pancreatic trypsin act as endogenous inhibitors of pancreatic tumor growthAndrea Resovi, Perla Persichitti, Laura Brunelli, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Connective Tissue Research|May 7, 2015
Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenograftsDenise Pinessi, Paola Ostano, Patrizia Borsotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulatorGurmeet Kaur, Dorina Belotti, Angelika M Burger, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2013
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinibMassimo Zucchetti, Katiuscia Bonezzi, Roberta Frapolli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivativeGiulia Taraboletti, Gianluca Micheletti, Monica Rieppi, et al.
Pharmacological Research|April 29, 2026
HIJACKING CLIENT INSTABILITY TO SELECTIVELY DISRUPT HSP90-DRIVEN GLUCOCORTICOID RECEPTOR ACTIVATIONElisa Longhi, Andrea Magni, Luca Torielli, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|October 15, 2021
Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activityDenise Pinessi, Andrea Resovi, Fabio Sangalli, et al.
Angiogenesis|September 1, 2018
The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2)Marco Rusnati, Patrizia Borsotti, Elisabetta Moroni, et al.
International Journal of Cancer|June 12, 2014
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1Romina Dossi, Roberta Frapolli, Silvana Di Giandomenico, et al.
Pigment Cell & Melanoma Research|September 27, 2014
Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2Patrizia Borsotti, Carmen Ghilardi, Paola Ostano, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 9, 2023
Fibronectin fragments generated by pancreatic trypsin act as endogenous inhibitors of pancreatic tumor growthAndrea Resovi, Perla Persichitti, Laura Brunelli, et al.
Pageof 3